

# Transforming Patients' Lives

## Janssen Pharmaceutical Companies of Johnson & Johnson

Dedicated to addressing and solving some of the most important needs of our time in oncology, immunology, neuroscience, infectious diseases, vaccines, cardiovascular and metabolic diseases



**12**

Consecutive quarters of operational growth in the pharmaceutical segment


### FASTEST

Growing top 10 pharmaceutical company in U.S., Japan & Europe

SOURCE: IMS HEALTH

### Extending Global Reach

Emerging markets including China, Brazil, Russia and India comprise nearly 20% of worldwide pharmaceutical sales in the first quarter of 2013.



20%

**11**

new product launches since 2009



### Janssen Momentum

- Robust commercial and launch capabilities
- Growing market share
- Ensuring greater access to our medicines
- Strengthening presence in critical geographies
- Nearly doubled our footprint in emerging markets over the last five years

### Industry Leading Drug Pipeline

Approach to innovation has resulted in a revitalized product portfolio and an industry-leading pipeline of near- and long-term compounds in the areas of Cardiovascular and Metabolic disorders, Immunology, Infectious Diseases and Vaccines, Neuroscience and Oncology

**>10**

Potential NMEs (New Molecular Entities) anticipated to be filed by 2017. NMEs are newly discovered and developed drugs, medicines or therapies

**>25**

More than 25 significant brand line extensions anticipated by 2017

### Transformational Medical Innovation

Late stage products that are planned to be filed by 2017 are aimed at addressing serious unmet needs including:

- Hepatitis C
- Hematologic malignancies
- Rheumatoid Arthritis
- New vaccines to treat influenza, rabies and polio

### Well Prepared for Next Wave of Growth:

- Committed to addressing major unmet medical needs
- Unique model of innovation
- Five Johnson & Johnson global innovation centers